BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12831991)

  • 1. Intra-tumoral distribution of (64)Cu-ATSM: a comparison study with FDG.
    Obata A; Yoshimoto M; Kasamatsu S; Naiki H; Takamatsu S; Kashikura K; Furukawa T; Lewis JS; Welch MJ; Saji H; Yonekura Y; Fujibayashi Y
    Nucl Med Biol; 2003 Jul; 30(5):529-34. PubMed ID: 12831991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.
    Dence CS; Ponde DE; Welch MJ; Lewis JS
    Nucl Med Biol; 2008 Aug; 35(6):713-20. PubMed ID: 18678357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.
    Valtorta S; Belloli S; Sanvito F; Masiello V; Di Grigoli G; Monterisi C; Fazio F; Picchio M; Moresco RM
    J Nucl Med; 2013 Jul; 54(7):1106-12. PubMed ID: 23699667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models.
    Tanaka T; Furukawa T; Fujieda S; Kasamatsu S; Yonekura Y; Fujibayashi Y
    Nucl Med Biol; 2006 Aug; 33(6):743-50. PubMed ID: 16934693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose painting based on tumor uptake of Cu-ATSM and FDG: a comparative study.
    Clausen MM; Hansen AE; Lundemann M; Hollensen C; Pommer T; Munck Af Rosenschöld P; Kristensen AT; Kjær A; McEvoy FJ; Engelholm SA
    Radiat Oncol; 2014 Oct; 9():228. PubMed ID: 25319766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose.
    Aft RL; Lewis JS; Zhang F; Kim J; Welch MJ
    Cancer Res; 2003 Sep; 63(17):5496-504. PubMed ID: 14500386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation.
    Lewis JS; Sharp TL; Laforest R; Fujibayashi Y; Welch MJ
    J Nucl Med; 2001 Apr; 42(4):655-61. PubMed ID: 11337556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different distribution of (62) Cu ATSM and (18)F-FDG in head and neck cancers.
    Kositwattanarerk A; Oh M; Kudo T; Kiyono Y; Mori T; Kimura Y; Maruyama R; Fujibayashi Y; Fujieda S; Okazawa H
    Clin Nucl Med; 2012 Mar; 37(3):252-7. PubMed ID: 22310251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Copper-62 ATSM as a hypoxic tissue tracer in myocardial ischemia.
    Takahashi N; Fujibayashi Y; Yonekura Y; Welch MJ; Waki A; Tsuchida T; Sadato N; Sugimoto K; Nakano A; Lee JD; Itoh H
    Ann Nucl Med; 2001 Jun; 15(3):293-6. PubMed ID: 11545205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).
    Yuan H; Schroeder T; Bowsher JE; Hedlund LW; Wong T; Dewhirst MW
    J Nucl Med; 2006 Jun; 47(6):989-98. PubMed ID: 16741309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer.
    Takahashi N; Fujibayashi Y; Yonekura Y; Welch MJ; Waki A; Tsuchida T; Sadato N; Sugimoto K; Itoh H
    Ann Nucl Med; 2000 Oct; 14(5):323-8. PubMed ID: 11108159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer.
    Lohith TG; Kudo T; Demura Y; Umeda Y; Kiyono Y; Fujibayashi Y; Okazawa H
    J Nucl Med; 2009 Dec; 50(12):1948-53. PubMed ID: 19910425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radio-copper-labeled Cu-ATSM: an indicator of quiescent but clonogenic cells under mild hypoxia in a Lewis lung carcinoma model.
    Oh M; Tanaka T; Kobayashi M; Furukawa T; Mori T; Kudo T; Fujieda S; Fujibayashi Y
    Nucl Med Biol; 2009 May; 36(4):419-26. PubMed ID: 19423010
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Dam TT; Hanaoka H; Nakajima T; Yamaguchi A; Okamura K; Chikuda H; Tsushima Y
    Mod Rheumatol; 2021 Mar; 31(2):350-356. PubMed ID: 32252574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).
    Dehdashti F; Grigsby PW; Lewis JS; Laforest R; Siegel BA; Welch MJ
    J Nucl Med; 2008 Feb; 49(2):201-5. PubMed ID: 18199612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM.
    Burgman P; O'Donoghue JA; Lewis JS; Welch MJ; Humm JL; Ling CC
    Nucl Med Biol; 2005 Aug; 32(6):623-30. PubMed ID: 16026709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report.
    Dehdashti F; Grigsby PW; Mintun MA; Lewis JS; Siegel BA; Welch MJ
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1233-8. PubMed ID: 12654432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Copper-64-diacetyl-bis (N4-methylthiosemicarbazone) accumulates in rich regions of CD133+ highly tumorigenic cells in mouse colon carcinoma.
    Yoshii Y; Furukawa T; Kiyono Y; Watanabe R; Waki A; Mori T; Yoshii H; Oh M; Asai T; Okazawa H; Welch MJ; Fujibayashi Y
    Nucl Med Biol; 2010 May; 37(4):395-404. PubMed ID: 20447549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study.
    Clausen MM; Hansen AE; Af Rosenschold PM; Kjaer A; Kristensen AT; McEvoy FJ; Engelholm SA
    Radiat Oncol; 2013 Nov; 8():262. PubMed ID: 24199939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multimodality functional imaging of spontaneous canine tumors using 64Cu-ATSM and 18FDG PET/CT and dynamic contrast enhanced perfusion CT.
    Hansen AE; Kristensen AT; Law I; McEvoy FJ; Kjær A; Engelholm SA
    Radiother Oncol; 2012 Mar; 102(3):424-8. PubMed ID: 22119225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.